Drug Search Results
More Filters [+]


Alternative Names: mrna-6231, mrna6231, mrna 6231
Latest Update: 2022-08-10
Latest Update Note: Clinical Trial Update

Product Description

mRNA‑6231 is a lipid nanoparticle (LNP)‑encapsulated mRNA-based therapeutic that encodes for mutein human interleukin 2, fused to human serum albumin (HSA‑IL2m), with the goal of achieving enhanced selectivity toward T regulatory cells. IL-2 through preferential expansion of Tregs is hypothesized to play a central role in restoring immune homeostasis. (Sourced from: https://investors.modernatx.com/news/news-details/2021/Moderna-Announces-First-Participant-Dosed-in-Phase-1-Study-of-Its-IL-2-mRNA-Therapeutic/default.aspx)

Mechanisms of Action: IL2 Agonist

Novel Mechanism: Yes

Modality: Nucleic Acid

Route of Administration: Injection

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Moderna
Company Location: CAMBRIDGE MA 02139
Company CEO: Stéphane Bancel
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for mRNA-6231

Countries in Clinic: Australia

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Autoimmune Diseases



Trial Status


Primary Completion Date

Probability of Success




Autoimmune Diseases


Recent News Events